Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: the DIAN-TU-001 Randomized Clinical Trial
Olivia Wagemann,Haiyan Liu,Guoqiao Wang,Xinyu Shi,Tobias Bittner,Marzia A. Scelsi,Martin R. Farlow,David B. Clifford,Charlene Supnet-Bell,Anna M. Santacruz,Andrew J. Aschenbrenner,Jason J. Hassenstab,Tammie L. S. Benzinger,Brian A. Gordon,Kelley A. Coalier,Carlos Cruchaga,Laura Ibanez,Richard J. Perrin,Chengjie Xiong,Yan Li,John C. Morris,James J. Lah,Sarah B. Berman,Erik D. Roberson,Christopher H. van Dyck,Douglas Galasko,Serge Gauthier,Ging-Yuek R. Hsiung,William S. Brooks,Jeremie Pariente,Catherine J. Mummery,Gregory S. Day,John M. Ringman,Patricio Chrem Mendez,Peter St. George-Hyslop,Nick C. Fox,Kazushi Suzuki,Hamid R. Okhravi,Jasmeer Chhatwal,Johannes Levin,Mathias Jucker,John R. Sims,Karen C. Holdridge,Nicholas K. Proctor,Roy Yaari,Scott W. Andersen,Michele Mancini,Jorge Llibre-Guerra,Randall J. Bateman,Eric Mcdade JAMA NEUROLOGY（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper